Apr 20, 2025

Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics:

• Introduction (0:00)
• Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42)
• Promising Novel Agents in Clinical Development; EGFR Exon 20...

Apr 10, 2025

Featuring an interview with Dr Justin F Gainor, including the following topics:

• Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00)
• Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of...

Apr 9, 2025

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics:

• Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00)
• Current role of other systemic therapy options for the treatment of...

Feb 11, 2025

Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics:

• Introduction (0:00)
• First-Line Treatment of Metastatic Disease (2:34)
• Adjuvant and Neoadjuvant Therapy (22:31)
• EGFR Exon 20 Insertion Mutations (34:21)
• Antibody-Drug Conjugates (42:45)

CME information and select...

Feb 9, 2025

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR Mutation-Positive NSCLC, Such as Nonmetastatic Disease, Exon 20 Insertion Mutations and Novel Agents — Helena Yu, MD